Combined inflammatory-lipid index and tumor markers for predicting the spatial localization of lesions in early-stage non-small cell lung cancer

炎症脂质指数与肿瘤标志物联合预测早期非小细胞肺癌病灶的空间定位

阅读:1

Abstract

OBJECTIVE: This study evaluated the predictive value of combined inflammatory-lipid indices and tumor markers in determining lesion localization in early-stage non-small cell lung cancer (NSCLC) and developed a predictive model. METHODS: A retrospective analysis of 206 early-stage NSCLC patients was conducted from December 1, 2023, to September 30, 2024. Patients were grouped based on tumor location: upper lobe and lower lobe. Significant predictors were identified through univariate and multivariate logistic regression analyses, leading to the development of a nomogram. Predictive performance was assessed using the receiver operating characteristic (ROC) curve and area under the curve (AUC). Model calibration was evaluated with a calibration plot, and decision curve analysis (DCA) was utilized to assess the model's relevance in clinical settings. RESULTS: Among the 206 patients, 135 (65.53%) had upper lobe tumors, and 71 (34.47%) had lower lobe tumors. Significant differences were found in white blood cell (WBC) count, lymphocyte count, α-hydroxybutyrate dehydrogenase (α-HBDH), high density lipoprotein cholesterol (HDL) triglycerides, low-density lipoprotein cholesterol (LDL), total cholesterol, carcinoembryonic antigen (CEA), serum ferritin (SF), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153), and carbohydrate antigen 199 (CA199) (all p < 0.05). Multivariate logistic regression identified WBC (OR: 1.46, 95% CI: 1.13-1.95, p = 0.007), a-HBDH (OR: 1.01, 95% CI: 1.00-1.03, p = 0.041), HDL (OR: 7.08, 95% CI: 1.50-36.16, p = 0.015), CEA (OR: 1.12, 95% CI: 1.02-1.23, p = 0.021), SF (OR: 1.01, 95% CI: 1.00-1.02, p = 0.020), CA153 (OR: 1.08, 95% CI: 1.00-1.16, p = 0.037), and CA199 (OR: 1.16, 95% CI: 1.07-1.27, p < 0.001) as independent risk factors for lower lobe tumor localization. An AUC of 0.806 was obtained for the nomogram (95% CI: 0.743-0.868), indicating good calibration, and showed favorable clinical utility based on decision curve analysis (DCA). CONCLUSION: WBC count, lymphocyte count, α-HBDH, HDL, CEA, SF, CA153, and CA199 are significant predictors of lesion localization in early-stage NSCLC. The developed nomogram, based on readily available clinical parameters, demonstrated strong predictive performance and may aid in individualized diagnosis and treatment planning. Further large-scale external validation is needed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。